These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16310447)

  • 1. The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk.
    Bresalier RS; Friedewald VE; Rakel RE; Roberts WC; Williams GW
    Am J Cardiol; 2005 Dec; 96(11):1589-604. PubMed ID: 16310447
    [No Abstract]   [Full Text] [Related]  

  • 2. The editor's roundtable: nonsteroidal antiinflammatory drugs and cardiovascular risk.
    Friedewald VE; Bennett JS; Packer M; Roberts WC; Williams GW
    Am J Cardiol; 2008 Oct; 102(8):1046-55. PubMed ID: 18929707
    [No Abstract]   [Full Text] [Related]  

  • 3. The Editor's Roundtable: the metabolic syndrome.
    Friedewald VE; Grundy S; Gotto AM; Haffner S; Denke MA; Hollander P; Roberts WC
    Am J Cardiol; 2007 Feb; 99(3):382-9. PubMed ID: 17261403
    [No Abstract]   [Full Text] [Related]  

  • 4. The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk.
    Friedewald VE; Ballantyne CM; Davidson MH; Guyton JR; Roberts WC
    Am J Cardiol; 2008 Sep; 102(5):559-67. PubMed ID: 18721512
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [COX-2 inhibitors and cardiovascular events].
    Kötter I
    Z Rheumatol; 2007 May; 66(3):243-4, 246. PubMed ID: 17334735
    [No Abstract]   [Full Text] [Related]  

  • 7. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
    Chan FK
    Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
    Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
    Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Editor's Roundtable: Endothelial dysfunction in cardiovascular disease.
    Friedewald VE; Giles TD; Pool JL; Yancy CW; Roberts WC
    Am J Cardiol; 2008 Aug; 102(4):418-23. PubMed ID: 18678298
    [No Abstract]   [Full Text] [Related]  

  • 10. [Coxibes--bullying of a drug class?].
    Müller P; Simon B
    MMW Fortschr Med; 2008 Jun; 150 Suppl 2():63-4. PubMed ID: 18712125
    [No Abstract]   [Full Text] [Related]  

  • 11. The global impact of the Framingham Heart Study: editor's introduction.
    Greenberg H
    Prog Cardiovasc Dis; 2010; 53(1):1-2. PubMed ID: 20620417
    [No Abstract]   [Full Text] [Related]  

  • 12. The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk.
    Sulkes D; Brown BG; Krauss RM; Segrest JP; Sniderman AD; Roberts WC
    Am J Cardiol; 2008 Mar; 101(6):828-42. PubMed ID: 18328849
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [2/3 COX-2 inhibitors].
    Fournel C; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Mar; (713):59-61. PubMed ID: 17419582
    [No Abstract]   [Full Text] [Related]  

  • 15. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 16. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The editor's roundtable: prehypertension.
    Roberts WC; Bakris GL; Black HR; Sica DA; Sulkes DJ
    Am J Cardiol; 2009 Oct; 104(8):1105-15. PubMed ID: 19801033
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
    Schug SA; Joshi GP; Camu F; Pan S; Cheung R
    Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periodontal infections and cardiovascular disease: is it a mere association?
    Humagain M; Nayak DG; Uppoor AS
    Kathmandu Univ Med J (KUMJ); 2006; 4(3):379-82. PubMed ID: 18603938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.